Presented at #ASCO24 :

ASC4FIRST: Asciminib, an agent that targets the myristoyl pocket of BCR::ABL, was compared with imatinib and with imatinib plus second-generation tyrosine kinase inhibitors. Outcomes were better with aciminib in both comparisons. nej.md/4bNNr3c

📢📢📢

CALL FOR NOMINATIONS NOW OPEN!

The Paul Farmer Lectureship and Award for Global Health Equity

at McGill University McGill School of Population and Global Health McGill Global Health Programs

Please share widely and nominate amazing people working on the ground to improve health equity!

mcgill.ca/spgh/about-us/…

“FDA’s flexibility needs to be counterbalanced with tough measures that ensure companies confirm the benefit of these drugs in a timely manner, & the agency must remove drugs from the market quickly if those confirmatory studies fail.

That’s the only way the system works.”

FDA approves liso-cel for mantle cell lymphoma: the goldilocks of CAR T?

cc Michael Dickinson

Join us for an insightful episode of Blood Cancer Talks with Dr. Ayalew Tefferi from Mayo Clinic Comprehensive Cancer Center. We dive deep into the pivotal TRANSFORM-1 and MANIFEST-2 #MF combination clinical trials, exploring nuances of myelofibrosis clinical trial endpoints. Don't miss it!

World leaders in academic/healthcare setting cell therapy manufacture
Hospital Clínic of Barcelona
In Spain 🇪🇸 . Hundreds of patients treated with CART to date in a successful nationwide collaborative effort.
#ISCT2024

Tune in to our new episode on updates in primary myelofibrosis with the MPN legend Dr. Ayalew Tefferi! We discussed navitoclax, pelabresib, & selinexor, along with practical tips on PMF management.

tinyurl.com/2muy3b72

👇Check out this clip on trial endpoints in PMF!

New Research: 4-year follow-up of GAIA/CLL13:

First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic #leukaemia thelancet.com/journals/lanon…

#CLL #leusm

Its always interesting to step back and look at melanoma screening recommendations around the world. In Australia (highest melanoma rates in the world) the official position statement of dermatologists is AGAINST screening the general population.

I have made so, so many videos about the American healthcare system. South Park just humbled me.

Navigating The American Healthcare System | South Park: The End Of Obesity youtu.be/VAfy26xs6e0?si… via YouTube

Simplified Risk Stratification Model for Patients With Waldenström Macroglobulinemia | Journal of Clinical Oncology ascopubs.org/doi/10.1200/JC…

Ok time for a thread.

Here’s the inside story about the most important drug you’ve never heard of, why it’s currently between 4.8 and 7 times too expensive, & why that could change this year.

But first, a little background (we promise it’s worth it) 🧵

John Green endTB

FDA Oncology Center of Excellence welcomed fellows of the FDA-AACR 2023-2024 Oncology Educational Fellowship to White Oak for a great mock ODAC and discussion!
#OCEProjectSocrates Rick Pazdur Jennifer Gao

Eddie Cliff AACR Lindor Qunaj Rick Pazdur Dr. Robert M. Califf Program On Regulation, Therapeutics, And Law Mikkael A. Sekeres MD, MS Greg Jennifer Gao Paul Kluetz Glad you enjoyed Project ODAC Odyssey! Tell your friends: Application window for the 2024-2025 FDA-AACR Oncology Educational Fellowship will open June 1! Applications due August 14. aacr.org/professionals/…

ORACLE RCT published The Lancet Haematology - oral 5’Aza in tfh-PTCL. Great collaboration with Lysa Lymphoma - 🇬🇧 recruitment through the TAP trials delivery network - funded by Cure Leukaemia
Fascinating survival data in a difficult disease area.
authors.elsevier.com/c/1j8UB8MsWYJi…

Intriguingly good data for AVR in treatment naive MCL

Thanks FDA Oncology AACR for a fantastic fellowship, culminating in Project ODAC Odyssey, a mock ODAC focused on analyses of molecularly-defined subgroups in oncology clinical trials

Was fun to represent the sponsor & pleased to report ODAC voted 9-0 in our favour!

Lindor Qunaj

👏👏👏

A similar issue is the dismal sharing of de-identified clinical trial data, despite publication-specific data sharing statements (not just blanket journal policies) stating such data would be available at time of publication. Eddie Cliff

Important discussion of endpoints in cancer screening studies and their potential pitfalls

Nature Medicine Saheli Sadanand

Hear hear Will! Congrats on an articulate testimony Senate Judiciary Committee building on a substantial body of work on patents